AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Vyome Holdings, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0036S6JZ9
1.79▼ 0.01 (-0.56%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
1.80
Day's Range
1.78 – 1.79
52-Week Range
1.75 – 6.56
Volume
1,690
Avg Volume
16.1K
Share Statistics
Shares Outstanding
Employees
18
Exchange
XNAS
Listed
2025-08-15
Share count as of August 12, 2026

Vyome Holdings, Inc. Common Stock (HIND) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Vyome Holdings, Inc. Common Stock (HIND)
What is Vyome Holdings, Inc. Common Stock's Market Cap?
Vyome Holdings, Inc. Common Stock's Market Cap is $12.6M, based on as-reported figures from SEC (XBRL) filings.
What is Vyome Holdings, Inc. Common Stock's Price / Sales?
Vyome Holdings, Inc. Common Stock's Price / Sales is 82.3×, based on as-reported figures from SEC (XBRL) filings.
What is Vyome Holdings, Inc. Common Stock's Revenue (TTM)?
Vyome Holdings, Inc. Common Stock's Revenue (TTM) is $152.7K, based on as-reported figures from SEC (XBRL) filings.
What is Vyome Holdings, Inc. Common Stock's Net Income (TTM)?
Vyome Holdings, Inc. Common Stock's Net Income (TTM) is -$10.9M, based on as-reported figures from SEC (XBRL) filings.
What is Vyome Holdings, Inc. Common Stock's EBITDA?
Vyome Holdings, Inc. Common Stock's EBITDA is -$11.4M, based on as-reported figures from SEC (XBRL) filings.
What is Vyome Holdings, Inc. Common Stock's Diluted EPS (TTM)?
Vyome Holdings, Inc. Common Stock's Diluted EPS (TTM) is -1.56, based on as-reported figures from SEC (XBRL) filings.
What is Vyome Holdings, Inc. Common Stock's EBITDA Margin?
Vyome Holdings, Inc. Common Stock's EBITDA Margin is -7446.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · HINDAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue—
YoY growth-46.0%—-40.5%-59.0%
Cost of goods sold—
Gross profit—
% of revenue43.2%—60.4%52.1%
Operating expenses
Depreciation and amortization—
Selling, general and administrative—
Research and development—
Total operating expenses—
% of revenue3243.3%—3767.7%24814.0%
Operating loss—
% of revenue-3200.0%—-3707.4%-24761.9%
Other income/(expense), net:
Interest expenses—
Interest income and other———
Fair value adjustment——
Total other income (expense), net—
Net loss
% of revenue-2669.9%—-3501.1%-24822.5%
Net loss attributable to non-controlling interest—
Net loss attributable to owners of the Company—
% of revenue-2543.3%—-3352.7%-24356.2%
Net Loss——
% of revenue-2669.9%———
Loss per common share – basic (in Dollars per share)——
Loss per common share – diluted (in Dollars per share)——